Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Intrinsic Value
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. [ Read More ]
The intrinsic value of one
AVDL
stock under the Base Case scenario is
20.5
USD.
Compared to the current market price of 16.91 USD,
Avadel Pharmaceuticals PLC
is
Undervalued by 18%.
Avadel Pharmaceuticals PLC's market capitalization is 1.5B USD.
AVDL stock price is 16.91 USD.
AVDL stock price (16.91 USD) is 18% less than its Intrinsic Value (20.5 USD).
AVDL stock (15.99 USD) is 5% less than its price (16.91 USD). Open Relative Valuation
AVDL has upside potential of 39% compared to the average analyst price target.
Open Wall St Estimates
AVDL's Revenue has been growing by 8% per year for the last 3 years.
AVDL has positive Gross Profit for the last twelve months.
AVDL's ROE (Return on Equity) has significantly decreased in the last 3 years from -7% to -481%, and is approaching profitability.
AVDL's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -29% to -359%, and is approaching profitability.
AVDL's long-term assets (165m USD) exceed its long-term liabilties (77m USD).
AVDL has negative Operating Income for the last twelve months.
AVDL has negative Net Income for the last twelve months.
AVDL's ROE (Return on Equity) for the past 12 months is negative and is equal to -481%.
AVDL's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -359%.
AVDL's Revenue is forecast to grow at a rate of 141% per year over the next 3 years.
AVDL has negative Free Cash Flow for the last twelve months.
AVDL's short-term assets (134m USD) exceed its short-term liabilties (37m USD).
AVDL's Altman Z-Score is very low and is equal to 0.9.
AVDL has negative three-year average ROE (Return on Equity): -303%. The company is not efficient at transforming stockholders' equity into net income.
AVDL has negative three-year average ROIC (Return on Invested Capital): -171%. The company is not efficient at using invested capital to generate operating income.
AVDL's D/E (Debt to Equity) is very low and is equal to 0.
AVDL doesn't generate enough operating income (-138m USD) to safely cover interest payments on its debt (5m USD).
Valuation Backtest
Avadel Pharmaceuticals PLC
Run backtest to discover the historical profit from buying and selling
AVDL
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Avadel Pharmaceuticals PLC
Balance Sheet Decomposition
Avadel Pharmaceuticals PLC
| Current Assets | 134.2m |
| Cash & Short-Term Investments | 105.1m |
| Receivables | 13.4m |
| Other Current Assets | 15.7m |
| Non-Current Assets | 30.5m |
| PP&E | 3.2m |
| Intangibles | 16.8m |
| Other Non-Current Assets | 10.5m |
| Current Liabilities | 36.9m |
| Accounts Payable | 11.4m |
| Accrued Liabilities | 25.2m |
| Other Current Liabilities | 261k |
| Non-Current Liabilities | 40.1m |
| Other Non-Current Liabilities | 40.1m |
Earnings Waterfall
Avadel Pharmaceuticals PLC
|
Revenue
|
28m
USD
|
|
Cost of Revenue
|
-846k
USD
|
|
Gross Profit
|
27.1m
USD
|
|
Operating Expenses
|
-165m
USD
|
|
Operating Income
|
-137.8m
USD
|
|
Other Expenses
|
-22.4m
USD
|
|
Net Income
|
-160.3m
USD
|
Free Cash Flow Analysis
Avadel Pharmaceuticals PLC
AVDL Profitability Score
Profitability Due Diligence
Avadel Pharmaceuticals PLC's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
Score
Avadel Pharmaceuticals PLC's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
AVDL Solvency Score
Solvency Due Diligence
Avadel Pharmaceuticals PLC's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Avadel Pharmaceuticals PLC's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AVDL Price Targets Summary
Avadel Pharmaceuticals PLC
According to Wall Street analysts, the average 1-year price target for
AVDL
is 23.56 USD
with a low forecast of 19.19 USD and a high forecast of 30.45 USD.
Ownership
AVDL Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
AVDL Price
Avadel Pharmaceuticals PLC
| Average Annual Return | 129.07% |
| Standard Deviation of Annual Returns | 259.56% |
| Max Drawdown | -91% |
| Market Capitalization | 1.5B USD |
| Shares Outstanding | 90 577 000 |
| Percentage of Shares Shorted | 12.6% |
Company Profile
Avadel Pharmaceuticals PLC
Country
Industry
Market Cap
Dividend Yield
Description
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
Contact
IPO
Employees
Officers
The intrinsic value of one
AVDL
stock under the Base Case scenario is
20.5
USD.
Compared to the current market price of 16.91 USD,
Avadel Pharmaceuticals PLC
is
Undervalued by 18%.
You don't have any saved screeners yet
